Lynx Investment Advisory Purchases Shares of 800 Moderna, Inc. (NASDAQ:MRNA)

Lynx Investment Advisory acquired a new position in shares of Moderna, Inc. (NASDAQ:MRNA) in the 2nd quarter, HoldingsChannel.com reports. The fund acquired 800 shares of the company’s stock, valued at approximately $95,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Quadrant Capital Group LLC boosted its holdings in shares of Moderna by 7.5% in the fourth quarter. Quadrant Capital Group LLC now owns 2,672 shares of the company’s stock valued at $266,000 after acquiring an additional 187 shares in the last quarter. International Assets Investment Management LLC raised its stake in shares of Moderna by 6,528.9% in the 4th quarter. International Assets Investment Management LLC now owns 387,656 shares of the company’s stock worth $38,552,000 after buying an additional 381,808 shares in the last quarter. abrdn plc lifted its holdings in shares of Moderna by 477.5% in the fourth quarter. abrdn plc now owns 483,574 shares of the company’s stock valued at $48,091,000 after buying an additional 399,843 shares during the period. Ontario Teachers Pension Plan Board purchased a new stake in shares of Moderna in the fourth quarter valued at $1,358,000. Finally, Hobbs Group Advisors LLC acquired a new stake in shares of Moderna in the fourth quarter worth $664,000. 75.33% of the stock is owned by institutional investors.

Insider Activity at Moderna

In other Moderna news, CFO James M. Mock sold 648 shares of Moderna stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $162.47, for a total transaction of $105,280.56. Following the completion of the transaction, the chief financial officer now directly owns 5,726 shares of the company’s stock, valued at $930,303.22. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Moderna news, Director Noubar Afeyan sold 15,000 shares of Moderna stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $117.08, for a total value of $1,756,200.00. Following the completion of the transaction, the director now owns 2,269,015 shares in the company, valued at approximately $265,656,276.20. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO James M. Mock sold 648 shares of the firm’s stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $162.47, for a total value of $105,280.56. Following the completion of the sale, the chief financial officer now owns 5,726 shares of the company’s stock, valued at $930,303.22. The disclosure for this sale can be found here. Insiders have sold a total of 396,239 shares of company stock valued at $55,563,937 in the last 90 days. 15.70% of the stock is owned by corporate insiders.

Moderna Stock Performance

Shares of MRNA traded down $1.45 on Tuesday, reaching $82.30. 5,116,690 shares of the stock traded hands, compared to its average volume of 4,162,379. Moderna, Inc. has a 12 month low of $62.55 and a 12 month high of $170.47. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.09 and a quick ratio of 3.91. The stock’s 50-day moving average price is $126.74 and its 200-day moving average price is $114.99. The firm has a market cap of $31.54 billion, a price-to-earnings ratio of -5.25 and a beta of 1.67.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, beating the consensus estimate of ($3.47) by $0.14. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The business had revenue of $241.00 million for the quarter, compared to analyst estimates of $128.41 million. During the same period in the previous year, the business earned ($3.62) EPS. The firm’s revenue was down 29.9% on a year-over-year basis. Equities analysts forecast that Moderna, Inc. will post -7.46 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently weighed in on MRNA. William Blair reaffirmed a “market perform” rating on shares of Moderna in a research note on Thursday, June 27th. Jefferies Financial Group reiterated a “buy” rating and set a $125.00 price target on shares of Moderna in a research note on Tuesday, April 9th. Royal Bank of Canada lowered shares of Moderna from an “outperform” rating to a “sector perform” rating and dropped their price target for the company from $125.00 to $90.00 in a research report on Monday. The Goldman Sachs Group decreased their price objective on shares of Moderna from $204.00 to $178.00 and set a “buy” rating for the company in a report on Friday. Finally, Canaccord Genuity Group lifted their target price on shares of Moderna from $91.00 to $106.00 and gave the stock a “hold” rating in a report on Friday, May 3rd. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $122.79.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.